Entinostat’s China Phase 3 Shows PFS Benefit Without Confirmed OS Gain
Long-term results from a randomized, double-blind Phase 3 trial of entinostat plus exemestane in China showed median overall survival of 38.6 months versus 29.2 months for placebo plus exemestane, but the difference was not…
